<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02239172</url>
  </required_header>
  <id_info>
    <org_study_id>FhCMB rPA83-001</org_study_id>
    <nct_id>NCT02239172</nct_id>
  </id_info>
  <brief_title>PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine</brief_title>
  <official_title>A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraunhofer, Center for Molecular Biotechnology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fraunhofer, Center for Molecular Biotechnology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study is to evaluate and compare the safety, reactogenicity, and
      tolerability of the PA83-FhCMB vaccine candidate delivered at 4 dose levels with Alhydrogel
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in antibody titer after three immunizations</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Anthrax</condition>
  <arm_group>
    <arm_group_label>12.5 µg + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 µg + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 µg + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 µg + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PA83-FhCMB</intervention_name>
    <arm_group_label>12.5 µg + Alhydrogel</arm_group_label>
    <arm_group_label>25 µg + Alhydrogel</arm_group_label>
    <arm_group_label>50 µg + Alhydrogel</arm_group_label>
    <arm_group_label>100 µg + Alhydrogel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Citizen or permanent resident of the US

          -  Male or female aged 18 to 49 years inclusive

          -  Able to give written informed consent

          -  Healthy, as determined by medical history, physical examination, vital signs, and
             clinical safety laboratory examinations at baseline

          -  Females should fulfill one of the following criteria:

               1. At least one year post-menopausal

               2. Surgically sterile

               3. Willing to use a medically approved form of contraception (eg, oral, implantable,
                  transdermal, or injectable hormonal contraceptive; intrauterine device; barrier
                  protection to include female condom, diaphragm, cervical cap, or male condoms in
                  conjunction with spermicide) for 30 days prior to first vaccination and through
                  the end of the study

               4. Willing to abstain from sexual intercourse for 30 days prior to first vaccination
                  and through the end of the study

          -  Women of childbearing potential must have a negative urine pregnancy test within 24
             hours preceding receipt of each dose

          -  Comprehension of the study requirements

          -  Expressed availability for the required study period

          -  Ability to attend scheduled visits and to be contacted by telephone throughout the
             follow-up period

        Exclusion Criteria:

          -  History of anthrax disease or receipt of anthrax vaccine

          -  Presence of significant uncontrolled medical or psychiatric illness (acute or chronic)
             including institution of new medical or surgical treatment or a significant dose
             alteration for uncontrolled symptoms or drug toxicity within 3 months of screening

          -  Positive serology for HIV-1 or HIV-2, or HBsAg or HCV antibodies

          -  Pregnancy or lactation

          -  Cancer or treatment for cancer, within the previous 3 years, excluding basal cell
             carcinoma

          -  Presence of any medical condition that may be associated with impaired immune
             responsiveness, including diabetes mellitus, per the investigator's discretion

          -  Presently receiving or history of receiving, during the preceding 3-month period, any
             medications or other treatments that may adversely affect the immune system

               1. This includes allergy injections, immune globulin, interferon, immunomodulators,
                  cytotoxic drugs, or systemic corticosteroids (oral or injectable; 20 mg/day x 14
                  days or longer)

               2. Radiation therapy

               3. Intranasal and topical corticosteroids will be allowed

          -  Receipt or planned administration of a non study vaccine within 14 days prior to
             vaccination and throughout the study period (30 days for live vaccines) Immunization
             on an emergency basis with Tetanus Toxoids Adsorbed for adult use (Td or Tdap) or
             influenza vaccine up to 14 days before or at least 14 days after a dose of study
             vaccine will be allowed

          -  History of anaphylactic type reaction to injected vaccines

          -  History of drug or chemical abuse in the year before the study

          -  Receipt of any investigational product or nonregistered drug within 30 days prior to
             vaccination or currently enrolled in any investigational drug study or intends to
             enroll in such a study within the ensuing study period

          -  Receipt of blood or blood products 8 weeks prior to vaccination or planned
             administration during the study period

          -  Donation of blood or blood products within 8 weeks prior to vaccination or at any time
             during the study

          -  Acute disease within 72 hours prior to vaccination

               1. Acute disease is defined as the presence of a moderate or severe illness (as
                  determined by the Investigator through medical history and physical examination)
                  with or without fever (≥38°C; 100.4°F), or an oral temperature of ≥38°C orally

               2. Study vaccine can be administered to persons with a minor illness

          -  History of immunodeficiency, chronic illness requiring continuous or frequent medical
             intervention, autoimmune disease, use of immunosuppressive medications, or ongoing
             therapy with systemic corticosteroids within 3 months prior to any planned vaccine
             dose. Inhaled and topical steroids are permitted. &quot;Burst&quot; therapy of steroids is
             permitted except within 2 weeks prior to vaccination.

          -  Evidence of psychiatric, medical and/or substance abuse problems during the past 6
             months that the investigator believes would adversely affect the subject's ability to
             participate in the trial

          -  Occupational or other responsibilities that would prevent completion of participation
             in the trial, including:

               1. US military or reservists who may receive the licensed anthrax vaccine (BioThrax)
                  or served during the Persian Gulf War between January and May, 1991. Such
                  individuals may be enrolled only if they provide their medical records, which can
                  then show proof that they have not received the licensed anthrax vaccine.

               2. Postal and other workers who may be exposed to anthrax or may have to take
                  BioThrax

          -  Any condition that, in the opinion of the investigator, might interfere with
             interpretation of data supporting the primary study objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research, Clinical Trials Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

